Dear Shareholders,

On behalf of the Board of Directors, I extend my gratitude to our shareholders for their investment and confidence in Pfizer during this transformative and exciting period. Serving as Lead Independent Director involves both privilege and responsibility and I am proud to serve on Pfizer’s Board of Directors. The full Board and I are dedicated to fulfilling our oversight duties on behalf of our shareholders.

2024 was a year of significant achievements for Pfizer. The Board’s continued robust oversight contributed to this performance and the company’s work to strengthen its position for the future. The Board focuses on ensuring that management delivers on its responsibility to drive long-term shareholder value creation. In doing so the Board engaged regularly with management over the course of the year to review the company’s corporate strategy and objectives, risk factors and competitive landscape. Key milestones in 2024 that demonstrate Pfizer’s progress, commitment to enhancing shareholder value and strong governance include:

• Successful integration of Seagen to create a leading oncology platform
• Robust cost realignment program expected to deliver approximately $4.5 billion in net cost savings by the end of 2025, most of which was achieved by year-end 2024
• Return of $9.5 billion in capital to shareholders through dividends
• Addition of two new Board members
• Appointments of a new Chief Scientific Officer and President, Research & Development, and a new Chief Strategy and Innovation Officer.

Pfizer has a world-class, highly engaged Board with Directors providing the relevant expertise, skills and experiences essential to overseeing the company’s business needs and overall strategy. In support of Pfizer’s science-led transformation, our Board includes members with deep knowledge in science and medicine, as well as those with significant experience in business leadership, finance, financial markets, public policy and technology.

We welcomed two distinguished leaders to our Board in 2024 following a thoughtful evaluation process to identify candidates who would complement the Board’s collective skills and bring a fresh business lens to discussions. Cyrus Taraporevala, former President and CEO of State Street Global Advisors, joined the Board in July, and Mortimer (Tim) Buckley, former Chairman and CEO of The Vanguard Group, Inc., joined the Board in October. Cyrus contributes to the Board’s extensive knowledge of global strategy, executive leadership in active and index investment management, and experience in driving organic and inorganic growth. At Vanguard, Tim led a global and growing organization, overseeing multiple business segments. He also previously served as both Chief Technology Officer and Chief Investment Officer at Vanguard.

On a related note, Helen Hobbs has decided to retire from the Board, effective in April 2025, and will not stand for re-election. We sincerely thank Helen for her contributions to the Board, and especially for her leadership as Chair of the Science and Technology Committee.

In closing, I would like to thank our shareholders for their ongoing support and the valuable feedback they provide throughout the year. I had the opportunity to meet directly with several investors over the last year, and hearing their perspectives and insights is helpful in informing our strategy, governance and oversight practices.

We value the partnership and engagement of our shareholders and encourage you to participate in the Annual Meeting by exercising your right to vote.

Mr. Shantanu Narayen

Lead Independent Director